Navigation Links
Replidyne Discontinues Phase III Trial
Date:4/23/2008

st-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile- associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-K filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are avail
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Replidyne Provides Strategic Update
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
4. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
7. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
8. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
9. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
10. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
11. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  ALPHAEON ... lifestyle healthcare and subsidiary of Strathspey ... acquired Physician Recommended Nutriceuticals (PRN) ® , a ... related products for dry eye and ... a transaction worth up to $55M. ...
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3Concord Medical Declares Special Dividend 2ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2
... 14, 2011 Life Technologies Corporation ... delivery technology specially designed for therapeutic applications that is ... available for licensing as part of a new out-licensing ... the novel proprietary siRNA delivery reagents by using new ...
... Imaging has achieved proof-of-concept with the first fully automated ... CT angiography (cCTA) study. This technology, the first to ... the potential to eliminate the need for a separate ... decrease patient radiation exposure. This work in progress is ...
Cached Medicine Technology:Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market 2Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market 3Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2
(Date:7/29/2014)... 2014 Current Back2Basics long-term drug rehab ... post foot surgery during his first six months of sobriety. ... – twice on one foot, once on the other– which ... my foot a year ago and was prescribed drugs that ... by a friend from home who’d recently completed the program. ...
(Date:7/29/2014)... 29, 2014 Couples rule at Maui's only ... Wailea. This September through November, the focus is on ... to couples of all ages and interests. Best of ... advantage of the Resort's popular Experience More package , ... yearly sale" is in full swing in the award-winning restaurants, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Multiple ... organization has announced the appointment of five new members ... the Coalition announced the election of its executive directors. ... 6 Board members and 2 Physician Advisors. These ... MSA Coalition mission of education, support, advocacy and research ...
(Date:7/29/2014)... 2014 Septic tanks have ... This score reflects a buyer's moderate ability to negotiate ... of suppliers, the product's widespread availability and the price-competitive ... Jordan Weinstein. IBISWorld estimates that there are more than ... of supplier options. However, recent demand growth and rising ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Ticketability.com has reduced ... have already been selling at lower prices on the secure ... receive a further discount on tickets that are priced lower ... selection of tickets available at Ticketability.com. , Theatergoers know that ... eager to find Phantom of the Opera tickets for sale ...
Breaking Medicine News(10 mins):Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 3Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 2Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 3Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 4Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Phantom of the Opera Tickets for Sale: Ticketability.com Delights Customers with Phantom of the Opera Theatre Tickets While Seats Last 2
... mouse genetic system co-developed by researchers at the University of ... biologist Hui Zong has isolated the cellular origin for malignant ... oligodendrocyte precursor cells (OPCs) are the point of origin is ... the July 22 issue of the journal Cell . ...
... , THURSDAY, July 7 (HealthDay News) -- The female ancestor ... lived in the vicinity of present-day Britain and Ireland 20,000 ... scientists. It,s likely that climate changes that affected the ... habitats and interbreeding between brown bears and polar bears. This ...
... Identifying a suitable donor for leukemia and lymphoma patients ... now that results of two clinical trials show transplant ... are comparable to fully matched tissue, thanks in large ... special post-transplant chemotherapy. The finding means that nearly ...
... Family doctors are reluctant to disclose identifiable patient ... mostly in an effort to protect patient privacy. A ... Canada Research Chair in Electronic Health Information at the ... Ontario Research Institute recently found that during the peak ...
... Gender may be associated with an increased risk ... knees, according to research being presented at the American ... Diego. "Having articular cartilage lesions ... the knee) is considered a predictor of future osteoarthritis-a ...
... In the largest reported series yet to compare transcervical ... staging and restaging of non-small cell lung cancer (NSCLC), ... research presented at the 14th World Conference on Lung ... the Study of Lung Cancer (IASLC). Diagnostic yield ...
Cached Medicine News:Health News:Cellular origin of deadly brain cancer is identified 2Health News:Cellular origin of deadly brain cancer is identified 3Health News:Female Ancestor of All Living Polar Bears Was Brown 2Health News:Half-matched transplants widen pool of donors for leukemia and lymphoma 2Health News:Half-matched transplants widen pool of donors for leukemia and lymphoma 3Health News:New report explains why physicians are reluctant to share patient data 2
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Central platform with integrated neck. Piston ... utilizing an internal spring to recoil ... Cutting Block fits into precision milled ... blades sized 6.25 - 9.0mm. Designed ...
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
Medicine Products: